Mantle Cell Lymphoma Initial Therapy with Abbreviated R-CHOP Followed by (90)Yibritumomab tiuxetan: Ten year follow-up of the Phase 2 ECOG-ACRIN study E1499

Documenti analoghi

• Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499
  di: Smith, Mitchell R., et al.
  Pubblicazione: (2012)
• Response-Adapted Therapy for Aggressive non-Hodgkin's Lymphomas based on early [18F] FDG-PET Scanning: ECOG-ACRIN Cancer Research Group Study (E3404)
  di: Swinnen, Lode J., et al.
  Pubblicazione: (2015)
• A Phase II Trial of R-CHOP Followed by Radioimmunotherapy for Early Stage (Stages I/II) Diffuse Large B-Cell Non-Hodgkin Lymphoma: ECOG3402
  di: Witzig, Thomas E., et al.
  Pubblicazione: (2015)
• Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial
  di: Advani, Ranjana H., et al.
  Pubblicazione: (2011)
• Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms: An Eastern Cooperative Group Study (E2404)
  di: Ganjoo, Kristen, et al.
  Pubblicazione: (2013)